Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.
Real-world CAR-T therapy shows manageable cytokine and neurologic side effects, with most patients successfully treated with standard interventions.
CRS incidence 82.6% (grade≥2: 47%) and ICANS incidence 48.4% (grade≥2: 71.5%) with axi-cel/brexu-cel; most patients received tocilizumab for CRS; 49.8% received ICANS prophylaxis with anti-epileptics; incidences consistent with prescribing information but management is evolving. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- retrospective observational cohort (CIBMTR registry)
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Transplant Cell Ther
Why it surfaced
Largest real-world CIBMTR dataset on axi-cel/brexu-cel toxicity to date (n=927, 87 centers); directly relevant to CAR-T safety monitoring and management practice; provides benchmark incidence data for the evolving cardio-oncology toxicity landscape.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.